Literature DB >> 10879713

MR analysis of nasopharyngeal carcinoma: correlation of the pattern of tumor extent at the primary site with the distribution of metastasized cervical lymph nodes. Preliminary results.

M Wakisaka1, H Mori, N Fuwa, A Matsumoto.   

Abstract

The purpose of this study was to correlate the pattern of tumor extent of nasopharyngeal carcinoma at the primary site on magnetic resonance (MR) imaging with the distribution of cervical lymph node metastasis. MR images of 32 patients with biopsy-proven nasopharyngeal carcinoma were reviewed and classified into five patterns of tumor extent in correlation with the distribution of cervical lymphadenopathy. The assessment of cervical lymph node metastasis was done on the basis of the computed tomography (CT) findings. The tumor volume was also correlated with the occurrence of contralateral lymphadenopathy. Of the 32 patients, five (16%) presented as type 1, tumor limited to the nasopharyngeal mucosa; 12 (38%) as type 2a, tumor which had invaded either lateral side but did not extend over the roof of nasopharynx; three (9%) as type 2b, tumor which had invaded bilaterally across the midline but did not extend over the roof of nasopharynx; three (9%) as type 2c, tumor which had invaded mainly the skull base but did not cross the midline; and nine (28%) as type 3, tumor which had extended anteriorly to the nasal cavity without invasion. Twenty-five patients (78%) demonstrated cervical lymphadenopathy. Patients with type 1, type 2b and type 3 spread had frequent bilateral cervical lymphadenopathy; those with type 2a had only ipsilateral lymphadenopathy. There was statistical significance (P < 0.005) regarding the existence of contralateral lymphadenopathy with midline tumors as well as the absence of contralateral cervical lymphadenopathy with non-midline tumors. This study therefore suggests that the distribution of metastasized lymph nodes depends on the pattern of tumor extent at the primary site.

Entities:  

Mesh:

Year:  2000        PMID: 10879713     DOI: 10.1007/s003300051047

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  27 in total

Review 1.  Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis.

Authors:  P M Som
Journal:  AJR Am J Roentgenol       Date:  1992-05       Impact factor: 3.959

2.  Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival.

Authors: 
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-06-01       Impact factor: 7.038

3.  Current and future therapy of nasopharyngeal cancer.

Authors:  J S Cooper
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-15       Impact factor: 7.038

4.  Detection of recurrent nasopharyngeal carcinoma: MR imaging versus CT.

Authors:  V F Chong; Y F Fan
Journal:  Radiology       Date:  1997-02       Impact factor: 11.105

5.  Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure.

Authors:  A W Lee; Y F Poon; W Foo; S C Law; F K Cheung; D K Chan; S Y Tung; M Thaw; J H Ho
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

6.  Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts.

Authors:  R Lindberg
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

7.  Tumors of the nasopharynx and adjacent areas: MR imaging with Gd-DTPA.

Authors:  T Vogl; S Dresel; L T Bilaniuk; G Grevers; K Kang; J Lissner
Journal:  AJR Am J Roentgenol       Date:  1990-03       Impact factor: 3.959

8.  Volumetric analysis of tumor extent in nasopharyngeal carcinoma and correlation with treatment outcome.

Authors:  D T Chua; J S Sham; D L Kwong; K S Tai; P M Wu; M Lo; A Yung; D Choy; L Leong
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-10-01       Impact factor: 7.038

Review 9.  MR imaging in the management of extracranial malignant tumors of the head and neck.

Authors:  P A Hudgins; G S Gussack
Journal:  AJR Am J Roentgenol       Date:  1992-07       Impact factor: 3.959

10.  Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy.

Authors:  R T Hoppe; D R Goffinet; M A Bagshaw
Journal:  Cancer       Date:  1976-06       Impact factor: 6.860

View more
  5 in total

Review 1.  Nodal imaging in the neck: recent advances in US, CT and MR imaging of metastatic nodes.

Authors:  Takashi Nakamura; Misa Sumi
Journal:  Eur Radiol       Date:  2007-01-25       Impact factor: 5.315

2.  Volumetric MR imaging of oral, maxillary sinus, oropharyngeal, and hypopharyngeal cancers: correlation between tumor volume and lymph node metastasis.

Authors:  Yasuo Kimura; Misa Sumi; Yoko Ichikawa; Yosuke Kawai; Takashi Nakamura
Journal:  AJNR Am J Neuroradiol       Date:  2005-10       Impact factor: 3.825

3.  Factors associated with nodal metastasis in nasopharyngeal cancer: an approach to reduce the radiation field in selected patients.

Authors:  Natsuo Tomita; N Fuwa; Y Ariji; T Kodaira; N Mizoguchi
Journal:  Br J Radiol       Date:  2010-10-19       Impact factor: 3.039

4.  Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET.

Authors:  Shu-Hang Ng; Joseph Tung-Chieh Chang; Sheng-Chieh Chan; Sheung-Fat Ko; Hung-Ming Wang; Chun-Ta Liao; Yu-Chen Chang; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-09       Impact factor: 9.236

5.  A novel N staging system for NPC based on IMRT and RTOG guidelines for lymph node levels: Results of a prospective multicentric clinical study.

Authors:  Min Kang; Pingting Zhou; Tingting Wei; Tingting Zhao; Jianxiong Long; Guisheng Li; Haolin Yan; Guosheng Feng; Meilian Liu; Jinxian Zhu; Rensheng Wang
Journal:  Oncol Lett       Date:  2018-05-09       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.